Drug intelligence / Profile preview

TKT001-S

Development stage: Preclinical
Lead developer: Seren Pharmaceuticals
Modality: Small Molecules

Overview

TKT001-S is a preclinical-stage antifungal drug candidate under development by Seren Pharma. Targeted for the treatment of fungal infections, the specific mechanism of action and molecular target of TKT001-S remain proprietary and have not been disclosed in the company's public pipeline. It is currently being evaluated in preclinical studies to determine its efficacy and safety profile. The compound represents part of Seren Pharma's research and development efforts to expand therapeutic options for infectious diseases.

Beyond the preview

Go deeper on TKT001-S.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TKT001-S.

Explore the full profile